Roquefort Therapeutics (LON:COIL) Trading Down 10% – Here’s Why

Roquefort Therapeutics plc (LON:COIL)’s stock price traded down 10% during mid-day trading on Monday . The company traded as low as GBX 10.10 and last traded at GBX 10.80. 782,783 shares were traded during mid-day trading, an increase of 130% from the average session volume of 339,970 shares. The stock had previously closed at GBX 12.

Roquefort Therapeutics Stock Down 10.0%

The company has a quick ratio of 3.07, a current ratio of 2.80 and a debt-to-equity ratio of 8.07. The stock has a 50-day simple moving average of GBX 9.11 and a 200-day simple moving average of GBX 11.40. The firm has a market capitalization of £46.09 million, a PE ratio of -0.49 and a beta of 0.05.

Roquefort Therapeutics (LON:COIL) last released its earnings results on Wednesday, May 6th. The company reported GBX (2.19) earnings per share (EPS) for the quarter. Roquefort Therapeutics had a negative return on equity of 18.30% and a negative net margin of 57,057.07%.

Roquefort Therapeutics Company Profile

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.